We strongly advise you to harness analysis of Infinity Pharmaceuticals fundamentals to see if markets are presently mispricing the organization. We found thirty-five available reported financial drivers for Infinity Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Infinity Pharmaceuticals fundamentals including its Shares Owned by Institutions, Net Income, Short Ratio, as well as the relationship between Price to Sales and Debt to Equity . Please also validate Infinity Pharmaceuticals Price to Earning to confirm the company can sustain itself down the road.Use Infinity Pharmaceuticals to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of Infinity Pharmaceuticals to be traded at $1.7557 in 30 days
Infinity Pharmaceuticals Valuation Over Time
Infinity Pharmaceuticals Company SummaryInfinity Pharmaceuticals competes with NantKwest, Del Mar, Denali Therapeutics, VBI Vaccines, and Vascular Biogenic. Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 56 people.
Infinity Pharmaceuticals Z Score vs Number of Shares Shorted
Infinity Pharmaceuticals Inc is currently regarded as number one stock in z score category among related companies. It is currently regarded as number one stock in number of shares shorted category among related companies making about 319,355 of Number of Shares Shorted per Z Score.